Tandem Diabetes Care Inc (TNDM) CFO Leigh Vosseller Sells 10,000 Shares

Tandem Diabetes Care Inc (NASDAQ:TNDM) CFO Leigh Vosseller sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $65.14, for a total value of $651,400.00. Following the completion of the sale, the chief financial officer now directly owns 12,009 shares of the company’s stock, valued at approximately $782,266.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Leigh Vosseller also recently made the following trade(s):

  • On Thursday, May 16th, Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock. The shares were sold at an average price of $70.45, for a total value of $704,500.00.

Shares of TNDM traded up $3.77 during mid-day trading on Thursday, hitting $69.17. The stock had a trading volume of 1,948,325 shares, compared to its average volume of 1,908,983. The firm has a market cap of $3.80 billion, a PE ratio of -27.13 and a beta of 0.63. Tandem Diabetes Care Inc has a 52 week low of $11.62 and a 52 week high of $74.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.43 and a quick ratio of 2.13.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.10). The company had revenue of $66.00 million during the quarter, compared to analysts’ expectations of $47.55 million. Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. Tandem Diabetes Care’s revenue for the quarter was up 141.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.82) earnings per share. Sell-side analysts anticipate that Tandem Diabetes Care Inc will post -0.81 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in TNDM. Bremer Bank National Association bought a new stake in Tandem Diabetes Care during the first quarter worth about $31,000. PNC Financial Services Group Inc. bought a new stake in Tandem Diabetes Care during the fourth quarter worth about $44,000. IFP Advisors Inc lifted its stake in Tandem Diabetes Care by 78.4% during the fourth quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock worth $66,000 after purchasing an additional 772 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in Tandem Diabetes Care during the first quarter worth about $122,000. Finally, Advisor Group Inc. lifted its stake in shares of Tandem Diabetes Care by 38.2% in the 4th quarter. Advisor Group Inc. now owns 2,351 shares of the medical device company’s stock valued at $89,000 after acquiring an additional 650 shares during the last quarter. Institutional investors own 80.52% of the company’s stock.

TNDM has been the subject of a number of research reports. BidaskClub cut Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. ValuEngine lowered Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Piper Jaffray Companies upgraded Tandem Diabetes Care to an “overweight” rating and set a $67.00 target price on the stock in a report on Wednesday, February 27th. Leerink Swann started coverage on Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price on the stock. Finally, Svb Leerink started coverage on Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price on the stock. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $68.13.

ILLEGAL ACTIVITY NOTICE: “Tandem Diabetes Care Inc (TNDM) CFO Leigh Vosseller Sells 10,000 Shares” was originally published by Rockland Register and is the sole property of of Rockland Register. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://rocklandregister.com/2019/05/30/leigh-vosseller-sells-10000-shares-of-tandem-diabetes-care-inc-tndm-stock.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: What is the float in trading stocks?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.